When did apotex's ruxolitinib receive fda approval?

Apotex’s generic formulation of ruxolitinib (marketed under the brand name Jakafi Gen in the United States) received its FDA approval on September 12, 2019. This approval made the generic available to treat myelofibrosis and other indications for which the brand‑name drug was already approved.